Genomic Health, a life science company developing genomic-based clinical diagnostic tests for cancer, priced 5.0 million shares at $12, the low end of its proposed $12-$14 range. The company currently markets a test targeting early stage breast cancer patients and has performed 3,000 such tests so far this year. J.P. Morgan and Lehman Brothers were the underwriters on the deal. Expect the stock to begin trading today on the NASDAQ under the symbol "GHDX."
